Our Recommendations
- Statement on the Efficacy of the AstraZeneca COVID-19 Vaccine (ChAdOx1 nCoV-19) against the SARS-CoV-2 Variants (2021)
- Guidance for surveillance of SARS-CoV-2 variants: Interim guidance, 9 August 2021 (2021)
- Variants (2021)
- COVID Reference 2021.6 EN (2021)
- Déclaration sur l’efficacité du vaccin COVID-19 d’AstraZeneca (ChAdOx1 nCoV-19) contre les variants du SARS-CoV-2 (2021)
New Publications
- Update 80: What we know about new COVID-19 Variants of Concern - the latest on the global situation & Omicron BA.4/5 (2022)
- Fortalecendo a vigilância para a Variante de Preocupação (VOC) Ômicron (B.1.1.529): Informe técnico e ações prioritárias para estados-membros Sede da Organização Mundial da Saúde (2022)
- WHO’s Science in 5 Episode #64 - Why are experts concerned about Omicron? (2022)
- WHO’s Science in 5 Episode #63 - Omicron variant (2022)
- Методы обнаружения и описания вариантов SARS-CoV-2 – первое обновление. 20 декабря 2021 г. (2021)
Filter
37
Featured
Recommendations
8
Language
Document type
Fact sheets
17
Guidelines
6
Videos
6
Studies & Reports
3
Training Material
2
Resource Platforms
2
Manuals
1
Countries / Regions
Russia
3
Niger
2
Germany
2
West and Central Africa
2
France
2
Spain
2
East and Southern Africa
2
South Africa
2
Brazil
2
Mali
2
South Sudan
2
Colombia
1
Mexico
1
El Salvador
1
Turkey
1
Benin
1
Kazakhstan
1
Chile
1
Cameroon
1
Syria
1
Senegal
1
Congo-Brazzaville
1
Burkina Faso
1
Peru
1
Morocco
1
Qatar
1
Mauritania
1
Mozambique
1
Haiti
1
Dominican Republic
1
Venezuela
1
Latin America and the Carribbean
1
Jordan
1
Saudi Arabia
1
Congo, Democratic Republic of
1
Middle East and North Africa
1
Tunisia
1
United Kingdom
1
Portugal
1
Belarus
1
Israel
1
Southern Africa
1
Côte d’Ivoire / Ivory Coast
1
Bolivia
1
Argentina
1
Lebanon
1
Vietnam
1
Eastern Europe
1
Nicaragua
1
Egypt
1
Sudan
1
Yemen
1
Honduras
1
Chad
1
Libya
1
Iraq
1
Somalia
1
Ecuador
1
India
1
Madagascar
1
Cuba
1
Guatemala
1
Authors & Publishers
Publication Years
Category
Countries
14
The NY Times variant tracker is perhaps the most accessible and relevant publication for non-molecular biologists and the general public
Each coronavirus contains nearly 30,000 letters of RNA. This genetic information allows the virus to infect cells and hijack them to make new viruses.
n light of the potential risk posed by SARS-CoV-2 variants, in January 2021 WHO organized an ad hoc consultation to discuss the development of an R&D agenda in response to existing and emerging SARS-CoV-2 variants.
The key objectives were to identify the critical research questions related to var...
21 Dec 2021. Slideset updated regularly to include the latest data and guidance on COVID-19 vaccines, including implications of emerging SARS-CoV-2 variants
What are the variants circulating at this time? How are variants classified as variants of interest or concern? What does this mean for the public? Dr Maria Van Kerkhove explains in Science in 5 this week.
What do we know about the Delta variant so far? How can we assess our risk? What strategies should we apply to protect ourselves whether we are in a low vaccination or high vaccination setting? WHO’s Dr Maria Van Kerkhove explains in Science in 5.
Do the current batch of approved vaccines protect us from the Delta variant? What is the level of protection? If you can still get infected even after being fully vaccinated, then why should we vaccinate? WHO’s Chief Scientist Dr Soumya Swaminathan explains in Science in 5.
This document aims to describe a minimum set of surveillance activities recommended at the national level to detect and monitor the relative prevalence of SARS-CoV-2 variants and outline a set of activities for the characterization and assessment of risk posed by these variants. A set of indicators ...
Cet article fait partie d’une série de notes explicatives sur la mise au point et la distribution de vaccins.
This document aims to describe a minimum set of surveillance activities recommended at the national level to detect and monitor the relative prevalence of SARS-CoV-2 variants and outline a set of activities for the characterization and assessment of risk posed by these variants. A set of indicators ...
Orientations provisoires
9 août 2021
Le présent document vise à décrire un ensemble minimal d'activités de surveillance recommandées au niveau national pour détecter et surveiller la prévalence relative des variantes du SRAS-CoV-2 et à présenter un ensemble d'activités pour la caractér...
Временные рекомендации
9 августа 2021 г.
Цель данного документа - описать минимальный набор мероприятий по эпиднадзору, рекомендуемых на национальном уровне для вы...
Orientaciones provisionales
9 de agosto de 2021
El presente documento tiene por objeto describir un conjunto mínimo de actividades de vigilancia recomendadas a nivel nacional para detectar y supervisar la prevalencia relativa de las variantes del SRAS-CoV-2 y esbozar un conjunto de actividades pa...
Update on SARS-CoV-2 variant of concern Omicron
recommended
Update 70, 10 Dec. 2021
doi: https://doi.org/10.1101/2020.10.28.20221143
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
